Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 16/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30154195 | 1.00 | CTSK (0.44) | CTSKCYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL30136143 | 1.00 | CTSK (0.44) | CTSKCYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL19337957 | 0.89 | CTSK (0.43) | CTSK | |
| SCHEMBL10270529 | 0.88 | CTSK (0.47) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL24963652 | 0.87 | CTSK (0.42) | CTSKCYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL9741235 | 0.87 | CAPN1 (0.44) | CTSKCYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL13471117 | 0.87 | CYP2D6 (0.45) | CTSKCYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL10662435 | 0.87 | CAPN1 (0.44) | CTSKCYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL9741231 | 0.87 | CAPN1 (0.44) | CTSKCYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL7296730 | 0.87 | CAPN1 (0.44) | CTSKCYP1A2CYP2C9CYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2834234-B1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-13 | — | — | EP | disclosed |